Johnson & Johnson is predicting $3.5 billion in sales of its COVID-19 vaccine in 2022, this represents a 46% jump in sales.
The company has taken a lot of flak since it first started to market its vaccine.
The uptake for its shot has not fared well compared to its much-touted rivals.
The company said it would take a more aggressive stance on deals for its medical device unit.
J&J’s 2022 revenue forecast for the vaccine was above Wall Street estimates, which had been lowered due to safety concerns as well as low uptake in the United States.
The company reported sales of $2.39 billion for the COVID shot in 2021, missing its own target of $2.5 billion in a year marked by manufacturing stumbles, safety concerns, and uneven demand for a vaccine once touted as a promising tool for inoculating populations in hard-to-reach areas.
Edited by Jesus Chan
Do you want to add feedback to this story?
Please add a comment in the box below or send an email to firstname.lastname@example.org, Call us at 201-500-7715